News
- Author:
- Lucy Hicks
Publish date: September 19, 2024
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
News
- Author:
- Lucy Hicks
Publish date: September 18, 2024
Dr. Christie Bartels discussed how rheumatology clinics can be utilized to tackle two common risk factors for heart disease without adding addition...
News
- Author:
- Lucy Hicks
Publish date: September 9, 2024
Both extreme heat and cold were tied to more severe episodes of Raynaud phenomenon in a study of participants with systemic sclerosis.
News
- Author:
- Lucy Hicks
Publish date: August 22, 2024
Janus kinase (JAK) inhibitor-associated acne may be overlooked outside of dermatology, experts said.
News
- Author:
- Lucy Hicks
Publish date: August 2, 2024
Since 2014, opioid use for autoimmune rheumatic decreased by 15% annually while other management modalities increased or stabilized.
News
- Author:
- Lucy Hicks
Publish date: July 23, 2024
Costs were as much as 316% higher in patients diagnosed and treated more than 12 weeks after symptom onset.
News
- Author:
- Lucy Hicks
Publish date: July 2, 2024
The biosimilar is approved for all indications of the reference medication, Stelara, and will launch in February 2025.
News
- Author:
- Lucy Hicks
Publish date: July 1, 2024
The findings uncover “yet another example of a disease where antibodies getting into the brain are the problem.”
News
- Author:
- Lucy Hicks
Publish date: June 28, 2024
More than half of patients assigned to TAK-279 achieved ACR20 at 12 weeks, compared with 30% of patients assigned to placebo in a phase 2 clinical ...
News
- Author:
- Lucy Hicks
Publish date: June 28, 2024
Patients receiving sonelokimab experienced higher treatment response in ACR20, ACR50, and PASI90 than those in the placebo group.
News
- Author:
- Lucy Hicks
Publish date: June 28, 2024
The new draft guidance reflects updated scientific thinking on biosimilars, the agency said.
News
- Author:
- Lucy Hicks
Publish date: June 28, 2024
In a real-world trial, baricitinib was favored over TNF inhibitors in clinical and patient-reported outcomes after 12 weeks, but one expert caution...
News
- Author:
- Lucy Hicks
Publish date: June 14, 2024
Ongoing efforts aim to differentiate biologically refractory cases from cases with comorbid conditions and social factors that can contribute to tr...
News
- Author:
- Lucy Hicks
Publish date: June 12, 2024
The approval applies to patients weighing at least 63 kg, the announcement said.
News
- Author:
- Lucy Hicks
Publish date: June 10, 2024
After adjustment for confounding factors, younger age at breast cancer diagnosis and lower baseline weight were the strongest predictors of more th...
